- Home
- IKNA vs PYXS Comparison
IKNA vs PYXS Comparison
Compare IKNA & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- PYXS
- Stock Information
- Founded
- IKNA 2016
- PYXS 2018
- Country
- IKNA United States
- PYXS United States
- Employees
- IKNA N/A
- PYXS N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- IKNA Health Care
- PYXS Health Care
- Exchange
- IKNA Nasdaq
- PYXS Nasdaq
- Market Cap
- IKNA 61.8M
- PYXS 64.4M
- IPO Year
- IKNA 2021
- PYXS 2021
- Fundamental
- Price
- IKNA $1.08
- PYXS $1.09
- Analyst Decision
- IKNA Buy
- PYXS Strong Buy
- Analyst Count
- IKNA 2
- PYXS 6
- Target Price
- IKNA $3.00
- PYXS $9.20
- AVG Volume (30 Days)
- IKNA 95.3K
- PYXS 520.0K
- Earning Date
- IKNA 05-20-2025
- PYXS 05-20-2025
- Dividend Yield
- IKNA N/A
- PYXS N/A
- EPS Growth
- IKNA N/A
- PYXS N/A
- EPS
- IKNA N/A
- PYXS N/A
- Revenue
- IKNA N/A
- PYXS $16,146,000.00
- Revenue This Year
- IKNA N/A
- PYXS N/A
- Revenue Next Year
- IKNA N/A
- PYXS N/A
- P/E Ratio
- IKNA N/A
- PYXS N/A
- Revenue Growth
- IKNA N/A
- PYXS N/A
- 52 Week Low
- IKNA $0.97
- PYXS $0.83
- 52 Week High
- IKNA $1.94
- PYXS $5.39
- Technical
- Relative Strength Index (RSI)
- IKNA 37.62
- PYXS 51.47
- Support Level
- IKNA $1.22
- PYXS $1.05
- Resistance Level
- IKNA $1.29
- PYXS $1.33
- Average True Range (ATR)
- IKNA 0.09
- PYXS 0.11
- MACD
- IKNA -0.01
- PYXS 0.01
- Stochastic Oscillator
- IKNA 1.75
- PYXS 41.46
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.